Urology News and Research

Latest Urology News and Research

Radiation therapy may not improve chances of survival for bladder cancer patients: Study

In the largest study to date of a rare and deadly form of bladder cancer, researchers at Henry Ford Hospital in Detroit found radiation therapy may not improve a patient's chances for survival.

3 Jun 2010

Ablation technique as affective as conventional surgery for treating kidney cancer

A minimally invasive technique used to destroy kidney tumors with an electrically controlled heating probe showed similar effectiveness as surgical removal of tumors in curbing cancer recurrence rates for up to five years after treatment.

3 Jun 2010

Protox Therapeutics reports positive data from Phase 2b study of PRX302 in BPH

Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins, today announced positive six month data from its double-blind placebo controlled Phase 2b study of PRX302 (study name: TRIUMPH) in patients with moderate to severe benign prostatic hyperplasia (BPH) a bothersome urologic condition that affects the quality of life of more than 50 million men worldwide.

2 Jun 2010

CDRD, Vancouver Prostate Centre announce preferred collaboration agreement

The Centre for Drug Research and Development (CDRD) and the Vancouver Prostate Centre (VPC) today announced that they have signed a preferred collaboration agreement as the two organizations jointly strive to accelerate the discovery, development and commercialization of anti-cancer therapeutics.

2 Jun 2010

Shionogi Pharma presents study results of PSD502 for treatment of primary PE at AUA 2010

Shionogi Pharma, Inc., a U.S.-based group company of Shionogi & Co., Ltd., today presented data summarizing the results of two pivotal studies of the investigational new drug PSD502, a topical metered dose spray being developed for the treatment of primary premature ejaculation. These data were presented at the 2010 American Urological Association Annual Meeting in San Francisco.

2 Jun 2010

Cook Medical's Resonance Metallic Ureteral Stent demonstrates long-term success in 29-month clinical study

A 29-month clinical study demonstrated the long-term success of Cook Medical's Resonance® Metallic Ureteral Stent in providing drainage for patients with both benign and malignant upper urinary tract obstructions, according to results presented today at the 2010 Annual Meeting of the American Urological Association (AUA). The findings suggest that metallic stents provide adequate drainage and can be maintained in situ for 12 months without significant encrustation.

2 Jun 2010

Two Buffalo scientists develop first procedure-based HOST software system

Two Buffalo scientists have paired up to create technology that has the potential to revolutionize surgical training worldwide, developing the first procedure-based, hands-on surgical training software. Their patent-pending system, Hands-On Surgical Training, guides surgeons through real-time operative procedures using the Robotic Surgical Simulator - interface.

2 Jun 2010

UT Southwestern researchers compare TVT and TOT sling procedures for stress urinary incontinence

As part of a national clinical trial, UT Southwestern Medical Center researchers found little difference in effectiveness between two popular treatments for one of the most common ailments among American women: stress urinary incontinence.

2 Jun 2010

Men who refuse surgery for prostate cancer have 51% overall survival rate: Study

Men who refuse surgery for prostate cancer and instead opt for "watchful waiting" - monitoring cancer progression without undergoing treatment - have a significantly worse long-term survival rate than those patients that choose radiotherapy, according to researchers at Henry Ford Hospital in Detroit.

2 Jun 2010

Phase 3 pivotal REVIVE study data of VIVUS' avanafil for ED presented at 2010 AUA

VIVUS, Inc. today announced that data from the previously reported phase 3 pivotal REVIVE (TA-301) study, evaluating the safety and efficacy of the investigational drug avanafil for the treatment of erectile dysfunction (ED), were presented at the American Urological Association (AUA) 2010 Annual Meeting.

2 Jun 2010

Men with ED are at increased risk of high CACS: Researchers

In the largest study to date evaluating erectile dysfunction and coronary artery calcification, researchers at Mount Sinai School of Medicine have determined that men with ED are at a significantly increased risk of high coronary artery calcification scores, a known predictor of future cardiovascular events.

2 Jun 2010

NanoPowers announces closing of CHF 5 million series A financing

NanoPowers SA, a medical device company that leverages its unique artificial muscle technology to restore or improve muscle function, today announced the closing of a CHF 5 million ($4.5 million) series A financing. The financing round was led by Novartis Venture Funds. Also participating in the financing were Initiative Capital Romandie and Gran Plasa SA.

1 Jun 2010

Protox announces presentations on PRX302 for BPH at 2010 AUA Annual Meeting

Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins, today announced that two oral podium presentations on the company's lead candidate, PRX302, will be made at the 2010 Annual Meeting of the American Urological Association (AUA). These presentations will include six month data from the Phase 2b clinical study of PRX302 called TRIUMPH, in patients with moderate to severe benign prostatic hyperplasia (BPH).

1 Jun 2010

Shionogi Pharma presents data on PSD502 pivotal studies for primary premature ejaculation at 2010 AUA

Shionogi Pharma, Inc., a U.S.-based group company of Shionogi & Co., Ltd., today presented data summarizing the results of two pivotal studies of the investigational new drug PSD502, a topical metered dose spray being developed for the treatment of primary premature ejaculation (PE). These data were presented at the 2010 American Urological Association (AUA) Annual Meeting in San Francisco.

1 Jun 2010

Cook Medical launches BIGopsy Backloading Biopsy Forceps for accurate diagnosis of kidney cancers

Urologists treating patients with suspicious ureteral or kidney lesions now have a tool to help them more effectively make diagnoses. Cook Medical has introduced the BIGopsy Backloading Biopsy Forceps, a device designed and engineered to obtain large renal or ureteral tissue specimens up to 4 mm3 for cancer diagnosis. The larger sample size helps produce biopsy results without the need for repeat tissue-sampling procedures associated with other biopsy devices.

31 May 2010

NewYork-Presbyterian Hospital/Columbia University Medical Center announce presentations at American Urological Association meeting

Physician-scientists from NewYork-Presbyterian Hospital/Columbia University Medical Center will present their latest research findings at the American Urological Association Annual Meeting in San Francisco, May 29 to June 3.

31 May 2010

EDAP to showcase Ablatherm-HIFU technology and Sonolith i-sys lithotripter at AUA 2010 Annual Meeting

EDAP TMS SA, the global leader in therapeutic ultrasound, today announced it will have a strong presence in both the exhibition and the scientific program at the American Urological Association (AUA) 2010 Annual Meeting, being held May 29 – June 3, 2010 in San Francisco. EDAP will showcase its Ablatherm-HIFU technology and Sonolith i-sys lithotripter at its exhibition booth # 1938 of the Moscone Convention Center.

29 May 2010

FDA approves Cysview for detection of non-muscle-invasive papillary cancer of bladder

GE Healthcare, a unit of General Electric Company, today announced that the US Food and Drug Administration has approved Cysview (hexaminolevulinate HCl) for the detection of non-muscle-invasive papillary cancer of the bladder in patients with known or suspected bladder cancer.

29 May 2010

New GreenLight XPS Laser System launched for treatment of BPH

American Medical Systems, a leading provider of world-class devices and therapies for both male and female pelvic health, today announced the launch and immediate availability of its new GreenLight XPS (Xcelerated Performance System) for laser treatment of benign prostatic hyperplasia or enlarged prostate.

29 May 2010

VIVUS to present phase 3 data on avanafil for treatment of ED at AUA 2010

VIVUS, Inc. today announced that phase 3 data on avanafil, a next generation oral phosphodiesterase type 5 inhibitor therapy being investigated for the treatment of erectile dysfunction, will be presented next Tuesday at the American Urological Association 2010 Annual Meeting in San Francisco, California.

28 May 2010

Urology News and Research

Latest Urology News and Research

Radiation therapy may not improve chances of survival for bladder cancer patients: Study

Ablation technique as affective as conventional surgery for treating kidney cancer

Protox Therapeutics reports positive data from Phase 2b study of PRX302 in BPH

CDRD, Vancouver Prostate Centre announce preferred collaboration agreement

Shionogi Pharma presents study results of PSD502 for treatment of primary PE at AUA 2010

Cook Medical's Resonance Metallic Ureteral Stent demonstrates long-term success in 29-month clinical study

Two Buffalo scientists develop first procedure-based HOST software system

UT Southwestern researchers compare TVT and TOT sling procedures for stress urinary incontinence

Men who refuse surgery for prostate cancer have 51% overall survival rate: Study

Phase 3 pivotal REVIVE study data of VIVUS' avanafil for ED presented at 2010 AUA

Men with ED are at increased risk of high CACS: Researchers

NanoPowers announces closing of CHF 5 million series A financing

Protox announces presentations on PRX302 for BPH at 2010 AUA Annual Meeting

Shionogi Pharma presents data on PSD502 pivotal studies for primary premature ejaculation at 2010 AUA

Cook Medical launches BIGopsy Backloading Biopsy Forceps for accurate diagnosis of kidney cancers

NewYork-Presbyterian Hospital/Columbia University Medical Center announce presentations at American Urological Association meeting

EDAP to showcase Ablatherm-HIFU technology and Sonolith i-sys lithotripter at AUA 2010 Annual Meeting

FDA approves Cysview for detection of non-muscle-invasive papillary cancer of bladder

New GreenLight XPS Laser System launched for treatment of BPH

VIVUS to present phase 3 data on avanafil for treatment of ED at AUA 2010

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Urology News and Research

Latest Urology News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in